title: Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.
abstract: BACKGROUND
  Double filtration plasmapheresis (DFPP) and (IA) are both used to clear antibody. However, the clinical efficacy and safety of DFPP in patients with anti-glomerular basement membrane (anti-GBM) disease are unclear.
  
  
  METHODS
  The 28 enrolled patients diagnosed serologically and pathologically with anti-GBM disease from 2003 to 2013 included 16 treated with DFPP and 12 with IA, with all patients administered immunosuppressive agents. DFPP consisted of an EC50W filter for plasma separation and an EC20W filter for plasma fractionation. A double volume of plasma was processed, and each patient received a 30-40 g human albumin supplement during each session. IA consisted of 10 cycles per session, with 8-10 sessions performed daily or every other day and each session regenerating 30-60 L of plasma. Serum anti-GBM antibodies and IgG were measured, and urinary and blood tests were performed, before and after each procedure. Renal function and outcome were determined.
  
  
  RESULTS
  The 28 patients consisted of 13 males and 15 females, of median age 44.5 years (range, 22.5-57 years). Six patients had pulmonary hemorrhage and 18 had serum creatinine concentrations >500 umol/L. The average serum creatinine concentration at early onset of disease was 525 umol/L while the peak concentration was 813 umol/L. All patients showed progressive increases in serum creatinine and required CRRT during the course of disease. Pathological examination showed an average 73.9% of crescents (range, 54.6-95.4%).The clinical and pathological features of the DPPP and IA groups were similar. Efficacy of clearing anti-GBM antibody was similar in the two groups (59.0 vs. 71.2%, P = 1.00), although fewer patients in the DFPP group experienced reduced IgG (62.7 vs. 83.5%, p = 0.002). One patient each had a pulmonary hemorrhage and a subcutaneous hemorrhage during treatment, but there were no other serious complications. At the end of follow-up, patient survival and renal survival were similar in the DFPP and IA groups.
  
  
  CONCLUSIONS
  DPPP plus immunosuppressive therapy efficiently and safely removed anti-GBM antibodies. The fewer plasma-associated side effects and reduced loss of IgG suggest that DFPP may be a better treatment choice for anti-GBM disease, especially in patients with insufficient plasma.
authors.forename: Yi-yan
authors.initials: YY
authors.lastname: Zhang
authors.affiliation: National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, P, R, China. tang_dr@163.com.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Tang
authors.forename: Dong-mei
authors.initials: DM
authors.lastname: Chen
authors.forename: De-hua
authors.initials: DH
authors.lastname: Gong
authors.forename: Da-xi
authors.initials: DX
authors.lastname: Ji
authors.forename: Zhi-hong
authors.initials: ZH
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019867:Anti-Glomerular Basement Membrane Disease / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007163:Immunosorbent Techniques / Q000592:standards; D007164:Immunosorbents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009393:Nephritis / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods* / Q000592:standards; D055815:Young Adult
chemical_list: D007164:Immunosorbents
references.citation: Medicine (Baltimore). 1985 Jul;64(4):219-27
references.pmid: 3892220
references.citation: Transfus Apher Sci. 2010 Apr;42(2):115-6
references.pmid: 20117054
references.citation: South Med J. 2002 Dec;95(12):1411-8
references.pmid: 12597309
references.citation: Int J Artif Organs. 1999 Feb;22(2):81-7
references.pmid: 10212042
references.citation: Autoimmun Rev. 2013 Sep;12(11):1101-8
references.pmid: 23806563
references.citation: J Clin Apher. 2007;22(5):270-6
references.pmid: 17722046
references.citation: Ther Apher Dial. 2009 Aug;13(4):373-7
references.pmid: 19695077
references.citation: Nephron Clin Pract. 2005;99(2):c49-55
references.pmid: 15637429
references.citation: Ther Apher Dial. 2009 Aug;13(4):278-81
references.pmid: 19695059
references.citation: Autoimmun Rev. 2012 Dec;12(2):169-73
references.pmid: 22546293
references.citation: Transfusion. 2004 Nov;44(11):1621-5
references.pmid: 15504168
references.citation: Nephron Clin Pract. 2003;94(3):c59-68
references.pmid: 12902632
references.citation: Transplantation. 2007 Dec 27;84(12 Suppl):S30-2
references.pmid: 18162985
references.citation: Ann Intern Med. 2001 Jun 5;134(11):1033-42
references.pmid: 11388816
references.citation: N Engl J Med. 2010 Jul 22;363(4):343-54
references.pmid: 20660402
references.citation: Intern Med J. 2012 Jun;42(6):672-6
references.pmid: 22032242
references.citation: Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Apr;28(4):628-33
references.pmid: 2214405
references.citation: Nephrology (Carlton). 2004 Apr;9(2):100-4
references.pmid: 15056270
references.citation: Ther Apher Dial. 2005 Oct;9(5):391-5
references.pmid: 16202013
references.citation: Adv Anat Pathol. 2012 Mar;19(2):111-24
references.pmid: 22313839